U.S.Stem Cell, Inc. is a biotechnology company, which engages in the discovery, development, and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The company is headquartered in Sunrise, Florida. The company went IPO on 2008-02-19. Stem Cell, Inc. is a biotechnology company. The firm is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The myoblast cells to be injected are gene-modified prior to injection by an adenovirus vector so that they will release extra quantities of stromal derived factor - 1 or SDF-1 protein. The Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. The company is also investigating the use of adipose cells in a variety of clinical applications.
How did USRM's recent EPS compare to expectations?
The most recent EPS for US Stem Cell Inc is $, expectations of $.
How did US Stem Cell Inc USRM's revenue perform in the last quarter?
US Stem Cell Inc revenue for the last quarter is $
What is the revenue estimate for US Stem Cell Inc?
According to of Wall street analyst, the revenue estimate of US Stem Cell Inc range from $ to $
What's the earning quality score for US Stem Cell Inc?
US Stem Cell Inc has a earning quality score of B+/51.153397. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does US Stem Cell Inc report earnings?
US Stem Cell Inc next earnings report is expected in 2022-06-29
What are US Stem Cell Inc's expected earnings?
US Stem Cell Inc expected earnings is $, according to wall-street analysts.
Did US Stem Cell Inc beat earnings expectations?
US Stem Cell Inc recent earnings of $ expectations.